Drug Shortage Report for MYLAN-LAMOTRIGINE
| Report ID | 213761 |
| Drug Identification Number | 02265516 |
| Brand name | MYLAN-LAMOTRIGINE |
| Common or Proper name | LAMOTRIGINE |
| Company Name | MYLAN PHARMACEUTICALS ULC |
| Market Status | MARKETED |
| Active Ingredient(s) | LAMOTRIGINE |
| Strength(s) | 150MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 100 BT |
| ATC code | N03AX |
| ATC description | ANTIEPILEPTICS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-12-19 |
| Actual start date | |
| Estimated end date | 2023-12-28 |
| Actual end date | 2024-01-08 |
| Shortage status | Resolved |
| Updated date | 2024-01-19 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
| Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2024-01-19 | French | Compare |
| v4 | 2024-01-19 | English | Compare |
| v3 | 2023-12-20 | English | Compare |
| v2 | 2023-12-19 | French | Compare |
| v1 | 2023-12-19 | English | Compare |
Showing 1 to 5 of 5